Evidence map›Paper›PMID 40655011›Full record

ArticlebioRxiv : the preprint server for biology2025

Dysregulated lymphatic remodeling promotes immunopathology during non-healing cutaneous leishmaniasis.

Lucy Fry, Flavia Neto de Jesus, Matheus Batista Carneiro, Hayden Roys, Anne Bowlin, Nathan C Peters, Pierre-Yves von der Weid, Tiffany Weinkopff

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Lucy FryDepartment of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA 72205.
Flavia Neto de JesusInflammation Research Network, Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, AB T2N 4N1, Calgary, Canada.
Matheus Batista CarneiroSnyder Institute for Chronic Diseases, Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, AB T2N 4N1, Calgary, Canada.
Hayden RoysDepartment of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA 72205.
Anne BowlinDepartment of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA 72205.
Nathan C PetersSnyder Institute for Chronic Diseases, Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, AB T2N 4N1, Calgary, Canada.
Pierre-Yves von der WeidInflammation Research Network, Snyder Institute for Chronic Diseases, Department of Physiology & Pharmacology, Cumming School of Medicine, University of Calgary, AB T2N 4N1, Calgary, Canada.
Tiffany WeinkopffDepartment of Microbiology and Immunology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA 72205.ORCID 0000-0002-5239-2486

Funding

Understanding Hesitant AdoptersP20GM103429 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Lawrence E Cornett · 2012 to 2026
$60.9M
Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021
$21.5M
Pilot Grant ProgramP30GM145393 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI MARK S SMELTZER · 2022 to 2026
$7.6M
J. NRSA TrainingTL1TR003109 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI SEXTON, KEVIN WAYNE · 2019 to 2023
$1.5M
Systems Pharmacology and Toxicology Training ProgramT32GM106999 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2013 to 2022
$1.4M
NCATS NIH HHS TL1 TR003109NCATS NIH HHS UL1 TR003107NIGMS NIH HHS P20 GM103429NIGMS NIH HHS P20 GM103625NIGMS NIH HHS P30 GM145393NIGMS NIH HHS T32 GM106999
6 · The paper itself

Abstract

Cutaneous leishmaniasis (CL) is a vector borne disease that is endemic to tropical and sub-tropical regions of the world disproportionately affecting those of low socioeconomic status. The combined role of the parasite and the host's immune response in determining disease severity has made it challenging to discover new anti-leishmanial treatments. Previous work from our lab has established that the dermal lymphatic network is necessary for wound resolution in a model of healing CL with

Indexed as

LeishmaniaLeishmaniasislymphangiogenesislymphatic endothelial cells

Identifiers

PMID40655011
PMCPMC12247974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.